Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) is now available.
Cizzle Biotechnology has appointed Professor Dawn Coverley as Chief Scientific Officer to enhance its global licensing and partnership strategy. This move coincides with the successful technical completion of the CIZ1B biomarker assay, poised to become a scalable solution for early lung cancer detection, potentially impacting the company’s market reach and patient care standards.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer specializing in a non-invasive, cost-effective blood test using the CIZ1B biomarker for early lung cancer detection. The company focuses on commercial royalty-bearing arrangements for its proprietary technology and collaborations with cancer care centers.
Average Trading Volume: 617,025
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £6.14M
See more data about CIZ stock on TipRanks’ Stock Analysis page.
